Highest-materiality recent filing
Supernus and Indivior announce all-stock merger of equals to create CNS-focused biopharma company
All-stock merger of equals between Supernus and Indivior; combined company to have four established CNS/behavioral health franchises.
Supernus and Indivior file investor presentation for proposed merger of equals; terms undisclosed
Conference call held August 3, 2026 at 8:30 a.m. ET to discuss merger of equals.
Supernus Q2 revenue up 32% to $219.1M; raises FY guidance; announces merger with Indivior
Total revenues $219.1M, +32% YoY; growth products revenue $175.7M, +52% YoY.
Supernus to merge with Indivior in all-stock deal; Indivior holders to own 56.5%
Each Supernus share converts to 1.5401 Indivior shares; fixed exchange ratio, no adjustment for market changes.
Supernus to report Q2 2026 results on August 4, 2026
Earnings release after market close on Tuesday, August 4, 2026.
Supernus shareholders approve all proposals, including equity plan share increase
Elected Class I directors Frederick M. Hudson (45.1M for) and Charles W. Newhall, III (41.7M for).
Supernus to pay $33.4M CVR milestone payment after Milestone 1 achieved March 18
Milestone 1 under July 2025 CVR Agreement achieved on March 18, 2026; triggers $0.50 per CVR payment.
Supernus Q1 revenue $207.7M (+39% YoY); growth products up 56%; reaffirms FY2026 guidance
Total revenues $207.7M, up 39% YoY; combined growth product revenues $149.1M (+56%).
Supernus to report Q1 2026 results on May 5, 2026 after market close
Results announced after close May 5, 2026; conference call at 4:30 PM ET.
Supernus acquires NV-5138/SPN-820 assets from Navitor; up to $350M in milestones
Supernus buys all IP, inventory, and regulatory materials for CNS compound NV-5138 (SPN-820).
Supernus Q4 revenue $211.6M (+21% YoY), FY revenue $719M (+9%); FY26 guidance $840-870M
Record Q4 total revenue $211.6M (+21% YoY); full year $719.0M (+9% YoY).
Supernus raises CEO salary to $1.067M, awards $847K bonus and equity grants
CEO salary increased to $1,067,100 from $1,036,000; 2025 bonus $846,930.
Supernus schedules Q4 2025 earnings release for Feb 24, 2026 after market close
Q4 and full year 2025 results to be reported after market close on February 24, 2026.
Supernus amends 2018 merger agreement milestone terms with Reich Consulting
First Amendment to Merger Agreement dated September 12, 2018, entered on January 22, 2026.
Supernus Q3 rev $192M, up 9%; growth products up 52%; ONAPGO supply constraint
Total revenues $192.1M (+9% YoY); combined growth product sales $149.2M (+52%).
Supernus schedules Q3 2025 earnings release for Nov 4 after market close
Financial results to be released after market close on Tuesday, November 4, 2025.
Supernus closes Sage acquisition for $8.50/share + CVRs; pro forma shows $118M H1 loss
Acquisition closed July 31, 2025; Supernus paid $8.50 per share cash plus CVRs up to $3.50 per share.
Supernus Q2 2025: Qelbree +31%, Sage acquisition closed, guidance raised
Total revenues Q2 2025: $165.5M vs $168.3M; non-GAAP rev ex-Trokendi/Oxtellar up 17% YoY.
Supernus appoints Frank Mottola as Chief Technical Operations Officer, effective June 16, 2025
Frank Mottola promoted from SVP, Quality, GMP Operations and IT to Chief Technical Operations Officer.
Supernus closes Sage acquisition for $8.50/share + up to $3.50 CVR; ~$561M cash, accretive in 2026
Total cash consideration ~$561M; 36.3M shares (58%) tendered; merger closed July 31, Sage wholly owned.
Supernus announces Q2 2025 earnings release and conference call on Aug 5, 2025
Press release states Q2 2025 results will be reported after market close on August 5, 2025.
Supernus stockholders elect directors, approve say-on-pay and KPMG ratification
Carolee Barlow and Jack Khattar re-elected as Class I directors; ~46.1M and ~46.5M votes for, respectively.
Supernus acquires Sage Therapeutics for up to $795M ($12/share including CVR)
Supernus to acquire Sage via tender offer at $8.50/share cash plus CVR up to $3.50/share, total up to $795M.
Supernus receives Paragraph IV ANDA filings for Qelbree; patents expire 2029-2035
Received Paragraph IV notice letters for ANDA of viloxazine ER capsules 100, 150, 200 mg.
Supernus Q1 2025: Qelbree sales +44% to $64.7M; ONAPGO launched; total revenue +4% to $149.8M
First quarter 2025 total revenue $149.8M, up 4% YoY; operating loss $(10.3)M vs $(3.2)M in prior year.
Supernus to announce Q1 2025 results and host call on May 6
Q1 2025 financial results to be reported after market close on Tuesday, May 6, 2025.
Supernus FY 2024 rev $661.8M; Qelbree +72%; ONAPGO approved; SPN-820 Phase 2b fails
Full year 2024 revenue $661.8M (+9% YoY); Qelbree net sales $241.3M (+72%) and GOCOVRI $130.8M (+9%).
Supernus approves executive salary increases and equity awards for 2025
CEO Jack Khattar base salary raised to $1,036,000; 2024 bonus $826,254; awarded 331,660 options and 198,996 PSUs.
Supernus SPN-820 Phase 2b misses primary endpoint in treatment-resistant depression
SPN-820 showed MADRS score change of -12.3 vs placebo -11.9 at Week 4; p=not significant.
Supernus schedules Q4 and full year 2024 earnings release and call for Feb 25, 2025
Earnings release expected after market close on Tuesday, February 25, 2025.
ONAPGO approved for continuous treatment of motor fluctuations in advanced Parkinson's patients not controlled by oral levodopa.
Supernus announces FDA label update for Qelbree with new pharmacodynamic and lactation data
FDA approved updated Qelbree label including serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition data.
Supernus updates Code of Ethics and Business Conduct on Dec 19, 2024
Board of Directors approved an updated Code of Ethics and Business Conduct on December 19, 2024.
Supernus Q3 revenue $175.7M (+14% YoY); raises FY guidance; Qelbree sales +68%
Net sales of Qelbree $62.4M (+68% YoY); GOCOVRI $35.6M (+8% YoY) in Q3 2024.
Supernus SPN-820 Phase 2a shows rapid antidepressant response: 50% MADRS rate at 4 hours
SPN-820 achieved 50.0% MADRS response rate and 35.0% remission rate at 4 hours post-dose in open-label Phase 2a study.
Supernus sets Q3 2024 earnings call for November 4 after market close
Earnings release scheduled for Monday, November 4, 2024, after market close.
Supernus SPN-820 Phase 2a data: rapid depressive symptom reduction with favorable tolerability
HAM-D6 score improved -6.1 at 2 hours, -9.6 at Day 10; MADRS improved -16.6 at 4 hours, -22.9 at Day 10.
Supernus to review Phase 2a data for SPN-820 in major depressive disorder on Oct 17
Company will host webcast and conference call on October 17, 2024 at 4:30 PM ET.
Supernus announces FDA accepted resubmission of SPN-830 NDA; PDUFA date Feb 1, 2025
FDA acknowledged resubmission of NDA for SPN-830 (apomorphine infusion device) for continuous treatment of motor fluctuations in Parkinson's disease.
Supernus Q2 revenues up 24% to $168.3M; Qelbree sales surge 92%; raises FY2024 guidance
Total Q2 revenues $168.3M (+24% YoY); Qelbree net sales $59.4M (+92% YoY); GOCOVRI $31.7M (+10% YoY)
Supernus resubmits NDA for SPN-830 apomorphine infusion for Parkinson's OFF episodes
Resubmitted NDA for SPN-830 (apomorphine infusion device) to FDA for continuous treatment of OFF episodes in Parkinson's disease.
Supernus announces Q2 2024 earnings date: Aug 6 after market close
Q2 2024 financial and business results to be reported after market close on Tuesday, August 6, 2024.
Supernus annual meeting results: directors elected, equity plan increase approved
Class III directors Georges Gemayel and Bethany Sensenig elected with ~48.4M and ~48.6M votes for, respectively.
Supernus reports positive interim Phase 2a data for SPN-817 in treatment-resistant seizures
75% median focal seizure reduction at 3-4 mg BID in maintenance period; 86% reduction in open-label extension.
Supernus to present interim Phase IIa data for SPN-817 on May 23
Interim data from open-label Phase IIa study of SPN-817 for treatment-resistant seizures to be reviewed at webcast on May 23, 2024.
Supernus Q1: Qelbree sales +75% to $45.1M; SPN-830 gets FDA CRL; FY guidance reiterated
Total revenue of $143.6M; Qelbree net sales surged 75% YoY to $45.1M (IQVIA Rx +31%).
Director John M. Siebert to retire from Supernus Board at June 2024 annual meeting
John M. Siebert, Ph.D., will retire from the Board effective at the Annual Meeting in June 2024.
Supernus to report Q1 2024 results after market close on May 8, 2024
Q1 2024 financial and business results will be released after market close on Wednesday, May 8, 2024.
Supernus receives FDA Complete Response Letter for SPN-830 (apomorphine infusion device)
FDA issued CRL stating NDA for SPN-830 (apomorphine infusion) not ready for approval.
Supernus Pharmaceuticals boosts CEO and executive compensation, grants equity
CEO Jack Khattar salary raised to $1,001,500; 2023 bonus of $830,588; options for 322,000 shares.
On April 22, 2024, John M. Siebert, Ph.D. informed Supernus Pharmaceuticals, Inc. (the “Company”) that he has decided to retire from the Company's Board of Directors (the "Board"), effective at the Company's Annual Meeting of Stockholders in June 2024
The Company expects Roman Bradel, Ph.D. to join the Company in March 2024 as its Vice President, Regulatory Affairs reporting to Frank Mottola, the Company’s Senior Vice President, Quality, GMP Operations and IT.
Tami T. Martin, R.N., Esq., the Company’s Senior Vice President, Regulatory Affairs, notified Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) of her retirement from the Company effective May 3, 2024.
As of August 17, 2023, the Board of Directors of Supernus Pharmaceuticals, Inc. (the “Company”) appointed Bethany L. Sensenig as a member of the Board of Directors of the Company and as a member of the Audit Committee.
On July 23, 2021, James P. Kelly, Executive Vice-President and Chief Financial Officer, notified Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) of his resignation from the Company to join another company.
On July 27, 2021, the Company appointed Timothy C. Dec to the position of Senior Vice-President and Chief Financial Officer.
Max materiality 0.90 · Median 0.62 · Most common event other_material